DDIT3 and diffuse large B-cell lymphoma: For DLBCL, there were no statistically significant differences in risk of death between patients treated with CHOP versus R-CHOP (HR = 1.330; P = not significant) or RCVP versus R-CHOP (HR = 1.118; P = not significant).